600%, page-47

Sanders
This sleeping giant is about to wake .
Once and for all we will see the hard work by the Anp board come to fruition.

People
Atl1103 for Acromegaly is going to put us on the world stage as well as get us “Early Income$“
Don’t forget we already have ODD in Europe and the USA which will speed up the approval of our drug in Europe.

“
As reported previously, the dosing frequency was reduced in this patient to 300 mg once weekly during the extending dosing due to mild/grade 1 thrombocytopenia (low platelet counts). Platelet counts stabilised at this reduced dosing frequency, and returned to normal levels during the follow-up period. As reported above, IGF-I levels normalised during the extended dosing period despite this reduction in dosing frequency.
There were no new significant adverse safety findings beyond those reported on 27 July 2016. ATL1103 appeared to be well-tolerated at the higher mg doses tested in the trial. No patient withdrew from the study and no serious adverse events reported.
In the period the US Food and Drug Administration (FDA) and European Commission granted Orphan Drug designation to ATL1103 for treatment of Acromegaly. Orphan Drug designation provides important incentives for continued drug development including market exclusivity, reduced fees, and potential access to grants and tax credits towards trial costs”

Then we will also be on the world stage re DMD (inflammation)
I’m 99% confident Atl1102 will get the green light for the start the trial in the first week of Feb 2018..
FDA has already approved Atl1102 lower dose for 6 months... so the RCHM ethics committee will follow suite.

I have explained Sarepta has a MC of $4 billion... they have the $$$ to take us out ...many multiples of where we are now with a MC $5 mill...
Sarepta want 100% of the DMD market ...Anp could be “first to market” re DMD ( inflammation)

On the other hand for only $200 million..A Large Pharma could take Anp out and get 2 drugs in phase 2. One with ODD in Europe and USA...

Key note.....
Sarepta has only 12% of DMD market and has a MC of $4 billion...
Anp has 3 Antisense drugs.... 2 in Phase 2 ...Active: Eap for Acromegaly in Europe...
MS waiting for FDA re higher dose..
DMD waiting approval by RCHM...

Go figure... one has to be excited....